115 related articles for article (PubMed ID: 12372522)
1. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency.
Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522
[TBL] [Abstract][Full Text] [Related]
2. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors.
Das J; Moquin RV; Lin J; Liu C; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2003 Aug; 13(15):2587-90. PubMed ID: 12852972
[TBL] [Abstract][Full Text] [Related]
4. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
Das J; Lin J; Moquin RV; Shen Z; Spergel SH; Wityak J; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2003 Jul; 13(13):2145-9. PubMed ID: 12798323
[TBL] [Abstract][Full Text] [Related]
5. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC
Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495
[TBL] [Abstract][Full Text] [Related]
6. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.
Chen P; Doweyko AM; Norris D; Gu HH; Spergel SH; Das J; Moquin RV; Lin J; Wityak J; Iwanowicz EJ; McIntyre KW; Shuster DJ; Behnia K; Chong S; de Fex H; Pang S; Pitt S; Shen DR; Thrall S; Stanley P; Kocy OR; Witmer MR; Kanner SB; Schieven GL; Barrish JC
J Med Chem; 2004 Aug; 47(18):4517-29. PubMed ID: 15317463
[TBL] [Abstract][Full Text] [Related]
7. A new strategy for the construction of the imidazo[1,5-a]quinoxalin-4-one ring system and its application to the efficient synthesis of BMS-238497, a novel and potent Lck inhibitor.
Chen BC; Zhao R; Bednarz MS; Wang B; Sundeen JE; Barrish JC
J Org Chem; 2004 Feb; 69(3):977-9. PubMed ID: 14750833
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of lck kinase.
Snow RJ; Cardozo MG; Morwick TM; Busacca CA; Dong Y; Eckner RJ; Jacober S; Jakes S; Kapadia S; Lukas S; Panzenbeck M; Peet GW; Peterson JD; Prokopowicz AS; Sellati R; Tolbert RM; Tschantz MA; Moss N
J Med Chem; 2002 Aug; 45(16):3394-405. PubMed ID: 12139450
[TBL] [Abstract][Full Text] [Related]
10. Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent.
Myers MR; He W; Hanney B; Setzer N; Maguire MP; Zulli A; Bilder G; Galzcinski H; Amin D; Needle S; Spada AP
Bioorg Med Chem Lett; 2003 Sep; 13(18):3091-5. PubMed ID: 12941341
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
12. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Koami T; Shiozawa F; Oka Y; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):112-6. PubMed ID: 19945867
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumour activity of new dendritic polyamines-(imide-DNA-intercalator) conjugates: potent Lck inhibitors.
Braña MF; Domínguez G; Sáez B; Romerdahl C; Robinson S; Barlozzari T
Eur J Med Chem; 2002 Jul; 37(7):541-51. PubMed ID: 12126773
[TBL] [Abstract][Full Text] [Related]
14. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
15. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
[TBL] [Abstract][Full Text] [Related]
16. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.
Burchat AF; Calderwood DJ; Friedman MM; Hirst GC; Li B; Rafferty P; Ritter K; Skinner BS
Bioorg Med Chem Lett; 2002 Jun; 12(12):1687-90. PubMed ID: 12039591
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
18. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
[TBL] [Abstract][Full Text] [Related]
19. 4-thiophenoxy-N-(3,4,5-trialkoxyphenyl)pyrimidine-2-amines as potent and selective inhibitors of the T-cell tyrosine kinase p56lck.
Moffat DF; Allen RA; Rapecki SE; Davis PD; O'Connell J; Hutchings MC; King MA; Boyce BA; Perry MJ
Curr Med Chem; 2004 Mar; 11(6):747-53. PubMed ID: 15032728
[TBL] [Abstract][Full Text] [Related]
20. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
